C. E. Arris, F. T. Boyle, A. H. Calvert, N. J. Curtin, J. A. Endicott, E. F. Garman, A. E. Gibson, B. T. Golding, S. Grant, R. J. Griffin, P. Jewsbury, L. N. Johnson, A. M. Lawrie, D. R. Newell, M. E. Noble, E. A. Sausville, R. Schultz and W. Yu, “Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles,” Journal of Medicinal Chemistry, Vol. 43, No. 15, 2000, 2797-2804. doi:10.1021/jm990628o

has been cited by the following article:

• TITLE: Design, Synthesis and Cancer Cell Line Activities of Pyrazolo[3,4-b]pyridine Derivatives

  AUTHORS: Mosaad Sayed Mohamed, Yara Essam El-Deen Awad, Salwa M. El-Hallouty, Moustafa El-Araby

  KEYWORDS: Pyridine; Pyrazolopyridine; Anticancer Activity; CDK Inhibitors; Kinase Inhibitor

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.2 No.3, September 27, 2012

  ABSTRACT: Starting from 4,6-dimethyl-2-oxo-(1H)-3-pyridinecarbonitrile 1 and 3-aminopyrazolopyridine 4, a series of cyanopyri- dine derivatives 3a-i, Schiff bases 5a-f, urea and thiourea derivatives 6a-b, amide derivatives 7a-h, pyridopyra- zolopy-rimidine 8a-b and pyridopyrazolotriazine 10a-b were synthesized. Activities of eleven representative compounds were evaluated against A-549 (lung), HEPG2 (liver) and HCT-116 (colon) cancer cell lines. The findings revealed that some of the synthesized compounds showed remarkable anticancer activities, especially 8b which displayed the highest activity among the tested compounds with IC50 equal to 2.9, 2.6 and 2.3 µmol. In addition to synthesis and biological activities, we present discussion about the rationale of the design and activity of the potent compound 8b using struc- ture-based modeling tools.